Revive Therapeutics Files For Patent On Oral Thin Film With Psilocybin

Revive Therapeutics (CSE: RVV) this morning announced that it has successfully completed research on an oral thin film delivery system with psilocybin, as well as filed for a related provisional patent for the technology with the US Patent and Trademark office.

The thin film technology with developed under a research partnership with the Reed Research Group at the University of Wisconsin-Madison. The film reportedly provides a unique delivery of psilocybin, which is to be used in the treatment of neurological, mental illness, and substance abuse disorders. Based on chitosan-tannin composite solutions, the film reportedly dissolved in testing in under five minutes after exposure to water.

Following the successful development of the product, Revive is now in discussions with lead contract manufacturers to assist in the clinical scale-up and manufacturing of the oral thin film. Future studies are to take place under US FDA Phase 1 and Phase 2 clinical studies for evaluation in humans.

“We are pleased with the final conclusion of the Research work and its successful results as it validates our drug delivery technology in delivering psychedelic pharmaceuticals and positions our oral thin film psilocybin product to become a potential novel treatment solution for various mental illness, neurological and substance abuse disorders. We continue to focus on building our intellectual property portfolio, advancing our psychedelics-based product pipeline to clinical trials and partnering with leading institutions.”

Michael Frank, CEO of Revive Therapeutics

Revive Therapeutics last traded at $0.425 on the CSE.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Is Agnico Eagle Seabridge Gold’s Mystery Lender?

This Gold Giant Is Building 1.5 Million More Ounces a Year | Agnico Eagle Q3 Earnings

This Gold Giant Was a Mess. Now It’s Back! | Barrick Mining Q3 2026 Earnings

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Shroom Boom! Has Michael Frank Brought Revive Back from the Dead?

Yesterday Revive Therapeutics (CSE: RVV) increased 81.8% from 5.5c to 10c on 4.1M shares traded....

Thursday, March 5, 2020, 08:46:25 AM

Growing Medical Acceptance of Psychedelics – The Daily Dive feat Derek Welsh of Revive Therapeutics

For our final episode of The Daily Dive this week, host Cassandra Leah is joined...

Friday, December 4, 2020, 01:00:00 PM

California Senate Votes to Decriminalize Psychedelics

California lawmakers have passed Senate Bill 58, a groundbreaking piece of legislation that decriminalizes the...

Saturday, September 9, 2023, 07:14:00 AM

Revive Therapeutics Includes Treating Omicron Variant In Bucillamine Research

Revive Therapeutics (CSE: RVV) announced today that it is expanding its research on oral drug Bucillamine....

Friday, December 3, 2021, 02:56:00 PM

Revive Therapeutics Selects Novotech As APAC Contract Research Organization

Revive Therapeutics (CSE: RVV) this morning has continued its push towards studying Bucillamine as a...

Wednesday, April 8, 2020, 09:37:45 AM